GLMD•benzinga•
Raymond James Maintains Outperform Rating for Galmed Pharmaceuticals: Here's What You Need To Know
Summary
Raymond James has decided to maintain its Outperform rating of Galmed Pharmaceuticals (NASDAQ:GLMD) and lower its price target from $14.00 to $5.00. Shares of Galmed Pharmaceuticals are trading down 22.69% over the last 24 hours, at $0.94 per share.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 3, 2022 by benzinga